Motivation: Localization of Cannabinoid type I receptor (CB1) across the whole brain with high temporal and spatial resolution would help a fundamental understanding of this receptor.
Goal(s): We sought to develop an in vivo MRI probe suitable for the cannabinoid system.
Approach: By chemically conjugating Rimonabantacid to the gadolinium chelate, we sought to create a novel paramagnetic probe TC1648·Gd. Introduction of this drug into mouse brains furthermore permits MRI-based measurement.
Results: Comparing the PET results with the TC1648.Gd, the high expression of CB1 in the hippocampus and the poor expression in the hypothalamus are highly consistent. TC1648.Gd enable imaging-based assessment of distribution of CB1.
Impact: The reagent is straightforward to produce and apply, and could immediately be used in a range of preclinical biomedical contexts. In future work, the idea of conjugating paramagnetic moieties to neuromodulatory agents could be extended to create additional MRI-detectable probes.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords